Literature DB >> 22472724

Asthma and bronchodilator responsiveness are associated with polymorphic markers of ARG1, CRHR2 and chromosome 17q21.

Hing Yee Sy1, Fanny W S Ko, Hong Yin Chu, Iris H S Chan, Gary W K Wong, David S C Hui, Ting Fan Leung.   

Abstract

OBJECTIVE: Asthma is caused by complex interactions between multiple genes. β2-Agonist is the standard rescue treatment to relieve asthma symptoms and bronchoconstriction. A genetic study for spirometric parameters helps to predict the responses to this antiasthma treatment. This study investigated the relationship between asthma and bronchodilator responsiveness (BDR) and eight asthma genes.
METHODS: Fifteen single-nucleotide polymorphisms in these genes were genotyped in 345 Chinese asthmatics and 464 controls. Gene-gene interactions were analysed by generalized multifactor dimensionality reduction (GMDR).
RESULTS: The diagnosis of asthma was associated with rs7216389 in ORMDL3 [odds ratio (OR) 0.74 and 95% confidence interval (95% CI) 0.56-0.99] and rs3756780 in ARG1 (OR 0.67, 95% CI 0.51-0.89) and BDR with rs2749935 in ARG1. However, none of these associations remained significant at 5% when adjusted for multiple testing by the Bonferroni correction or a false discovery rate. GMDR analyses revealed that rs7216389 in ORMDL3 and rs3756780 in ARG1 might interact for a risk of asthma. Individuals with high-risk genotypes had OR 1.66 (95% CI 1.24-2.23) for asthma when compared with those with low-risk genotypes. GMDR suggested a two-locus model with rs2749935 in ARG1 and rs2190242 in CRHR2 to be associated with BDR. Specifically, reversibility of forced expiratory volume in 1 s was higher in high-risk than that in low-risk patients [mean (95% CI): 10.7 (8.6-12.9) vs. 6.8 (5.9-7.6)%]; with the latter group showing higher forced expiratory volume in 1 s reversibility compared with high-risk controls [2.8 (1.4-4.3)%].
CONCLUSION: ARG1 and ORMDL3 may interact to determine the risk of asthma and ARG1 and CRHR2 to alter BDR in asthmatics. Nonetheless, this study is only hypothesis-generating as none of the single marker comparisons is significant when adjusted for multiple testing. These findings need to be confirmed in independent populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22472724     DOI: 10.1097/FPC.0b013e3283535d91

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  6 in total

Review 1.  Chinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthma.

Authors:  Jiangtao Lin; Kaisheng Yin; Nan Su; Mao Huang; Chen Qiu; Chuntao Liu; Shaoxi Cai; Chuangli Hao
Journal:  Ann Transl Med       Date:  2015-11

Review 2.  Chinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthma.

Authors:  Jiangtao Lin; Kaisheng Yin; Nan Su; Mao Huang; Chen Qiu; Chuntao Liu; Shaoxi Cai; Chuangli Hao
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

3.  Association between 17q12-21 variants and asthma in Japanese women: rs11650680 polymorphism as potential genetic marker for asthma.

Authors:  Yoshihiro Miyake; Keiko Tanaka; Masashi Arakawa
Journal:  DNA Cell Biol       Date:  2014-04-15       Impact factor: 3.311

Review 4.  A roadmap to multifactor dimensionality reduction methods.

Authors:  Damian Gola; Jestinah M Mahachie John; Kristel van Steen; Inke R König
Journal:  Brief Bioinform       Date:  2015-06-24       Impact factor: 11.622

Review 5.  Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy.

Authors:  Jesús Miguel García-Menaya; Concepción Cordobés-Durán; Elena García-Martín; José A G Agúndez
Journal:  Front Pharmacol       Date:  2019-05-21       Impact factor: 5.810

6.  Identification of differentially expressed genes and signaling pathways in chronic obstructive pulmonary disease via bioinformatic analysis.

Authors:  Xinwei Huang; Yunwei Li; Xiaoran Guo; Zongxin Zhu; Xiangyang Kong; Fubing Yu; Qiang Wang
Journal:  FEBS Open Bio       Date:  2019-09-29       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.